Literature DB >> 20339023

High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.

Hiroaki Fukumoto1, Takahiko Tokuda, Takashi Kasai, Noriko Ishigami, Hiroya Hidaka, Masaki Kondo, David Allsop, Masanori Nakagawa.   

Abstract

There is accumulating evidence that soluble amyloid-beta (Abeta) oligomers, rather than amyloid fibrils, are the principal pathogenic species in Alzheimer disease (AD). Here, we have developed a novel enzyme-linked immunosorbent assay (ELISA) specific for high-molecular-weight (HMW) Abeta oligomers. Analysis of Abeta oligomers derived from synthetic Abeta 1-42, by size-exclusion chromatography (SEC), revealed that our ELISA specifically detected HMW Abeta oligomers of 40-200 kDa. Using this ELISA, we detected significantly higher (P<0.0001) signals in cerebrospinal fluid (CSF) samples from 25 patients with AD or mild cognitive impairment (MCI), compared to 25 age-matched controls. As a test for discriminating between the AD/MCI and control groups, the area under the curve in receiver operating characteristic analysis for the CSF HMW Abeta oligomers was greater than that for CSF Abeta x-42. Furthermore, the CSF levels of HMW Abeta oligomers showed a negative correlation with Mini-Mental State Examination scores in the AD/MCI group. We conclude that the CSF HMW Abeta oligomers detected by our ELISA could be useful as a diagnostic marker for AD, and also as a potential surrogate marker for disease severity. Our results support the idea that soluble HMW Abeta oligomers play a critical role in the pathogenesis and progression of AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20339023     DOI: 10.1096/fj.09-150359

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  100 in total

Review 1.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.

Authors:  Colin L Masters; Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

2.  Parkinson disease: Progress towards a molecular biomarker for Parkinson disease.

Authors:  Penelope Foulds; David M A Mann; J Douglas Mitchell; David Allsop
Journal:  Nat Rev Neurol       Date:  2010-07       Impact factor: 42.937

3.  N-terminal engineering of amyloid-β-binding Affibody molecules yields improved chemical synthesis and higher binding affinity.

Authors:  Joel Lindgren; Anna Wahlström; Jens Danielsson; Natalia Markova; Caroline Ekblad; Astrid Gräslund; Lars Abrahmsén; Amelie Eriksson Karlström; Sebastian K T S Wärmländer
Journal:  Protein Sci       Date:  2010-12       Impact factor: 6.725

4.  Effects of peptides derived from terminal modifications of the aβ central hydrophobic core on aβ fibrillization.

Authors:  Cyrus K Bett; Wilson K Serem; Krystal R Fontenot; Robert P Hammer; Jayne C Garno
Journal:  ACS Chem Neurosci       Date:  2010-08-26       Impact factor: 4.418

Review 5.  The keystone of Alzheimer pathogenesis might be sought in Aβ physiology.

Authors:  D Puzzo; W Gulisano; O Arancio; A Palmeri
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

6.  Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis.

Authors:  Oliver Wirths; Christian Erck; Henrik Martens; Anja Harmeier; Constanze Geumann; Sadim Jawhar; Sathish Kumar; Gerd Multhaup; Jochen Walter; Martin Ingelsson; Malin Degerman-Gunnarsson; Hannu Kalimo; Inge Huitinga; Lars Lannfelt; Thomas A Bayer
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

Review 7.  Dementia in 2010: Paving the way for Alzheimer disease drug development.

Authors:  Kaj Blennow
Journal:  Nat Rev Neurol       Date:  2011-02       Impact factor: 42.937

Review 8.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

Authors:  Sergio T Ferreira; William L Klein
Journal:  Neurobiol Learn Mem       Date:  2011-09-06       Impact factor: 2.877

Review 9.  Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Authors:  Jun Ku Chung; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Danielle Uy; Philip Gerretsen; Fernando Caravaggio; M Mallar Chakravarty; Ariel Graff-Guerrero
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-29       Impact factor: 4.105

10.  Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls.

Authors:  Thomas J Esparza; Hanzhi Zhao; John R Cirrito; Nigel J Cairns; Randall J Bateman; David M Holtzman; David L Brody
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.